Bone marrow is scientifically validated as a therapeutic agent in the context of broken bones, particularly in the field of regenerative medicine and orthopedic surgery. Bone marrow contains mesenchymal stem cells (MSCs), which have the ability to differentiate into bone, cartilage, and other connective tissues. This property is harnessed in bone marrow aspirate concentrate (BMAC) therapies, where marrow is harvested (usually from the iliac crest), concentrated, and then injected or implanted at the site of bone fractures or defects.

Numerous preclinical and clinical studies support the efficacy of bone marrow-derived cells in enhancing bone healing, especially in cases of non-union or delayed union fractures. For example, a landmark study by Hernigou et al. (2005, Journal of Bone and Joint Surgery) demonstrated that autologous bone marrow grafting significantly improved healing rates in patients with tibial non-union. The osteogenic, osteoinductive, and osteoconductive properties of the marrow's cell populations, along with growth factors present in the marrow, contribute to the repair and regeneration of bone tissue.

While bone marrow is not used as a dietary supplement to treat broken bones, its direct application in orthopedic procedures is well-supported. However, the degree of benefit can vary based on patient factors, fracture type, and technique. Overall, bone marrow-based treatments represent a scientific and clinically validated adjunct to standard bone fracture management.